An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels

Overview of attention for article published in Journal of Neurology, April 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter: 5 X users
patent: 1 patent

facebook: 1 Facebook page
googleplus: 1 Google+ user

Citations

dimensions_citation: 92 Dimensions

Readers on

mendeley: 110 Mendeley

Summary X Patents Facebook Google+ Dimensions citations

So far, Altmetric has seen 1 Google+ post.

09 Apr 2015

An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without... An open-label trial…